Reblozyl

European Commission Approves Reblozyl for the Treatment of Transfusion-dependent β-Thalassaemia
Clinical News

European Commission Approves Reblozyl for the Treatment of Transfusion-dependent β-Thalassaemia

Bristol Myers Squibb (BMS) & Acceleron Pharma announced today that the European Commission approved Reblozyl (luspatercept) for the treatment of Transfusion-Dependent β-#Thalassaemia (TDT) in adult patients. Reblozyl has the potential to…
eThalED Webinar Series: Access to New Therapies – Reblozyl
News

eThalED Webinar Series: Access to New Therapies – Reblozyl

The 1st webinar for Medical Specialists organised in the context of TIF’s eThalEd online course is here. Dr Antonio Piga, Professor of Paediatrics & Dean of the Medicine School at…
TIF ITD2020 Webinar: The Patients‘ Perspective on the Accessibility & Affordability of Novel Therapies for Thalassaemia
News

TIF ITD2020 Webinar: The Patients‘ Perspective on the Accessibility & Affordability of Novel Therapies for Thalassaemia

9 patients with thalassaemia, members of TIF’s Patient Advocacy Group for Thalassaemia and Sickle Cell Disease (T-PAG), are discussing with the Thalassaemia International Federation the accessibility and affordability of the…
Reblozyl (luspatercept-aamt) Receives Positive CHMP Opinion for the Treatment of Adults with β-Thalassaemia
Clinical News

Reblozyl (luspatercept-aamt) Receives Positive CHMP Opinion for the Treatment of Adults with β-Thalassaemia

On 30 April 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product REBLOZYL, intended for the treatment of adults…
The 1st TIF Webinar for Medical Specialists Scheduled for 11 May
News

The 1st TIF Webinar for Medical Specialists Scheduled for 11 May

  The 1st webinar for Medical Specialists organised in the context of TIF’s eThalEd online course has just arrived! Dr Antonio Piga, Professor of Paediatrics & Dean of the Medicine School at…
Back to top button
Close
Close